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Summary Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase
inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity
was minimal. Possibilities for the more effective use of this agent are discussed.
Didox (M,3-4trihydroxybenzamide), an inhibitor of ribo-
nucleotide reductase, interferes with the synthesis of DNA by
blocking the production ofdeoxyribonucleotides. The cellular
content of the enzyme closely correlates with a cell's repli-
cative activity and so its inhibition could be a useful
approach in the treatment of malignant disease (Elford et al.,
1970). Didox has been shown to have anti-tumour effects in a
variety of experimental systems including L1210 and P388
leukaemias, B16 melanoma, Lewis' lung tumour and several
human tumour xenografts (Elford & Van't Reit, 1985). It is
more potent as an inhibitor of ribonucleotide reductase than
hydroxyurea (Elford et al., 1979).
A phase I study involving 34 patients with a variety of
cancers established the dose-limiting toxicity of didox as
disturbance of hepatic and renal function (Veale et al., 1988).
It was found that didox could be administered safely by slow
intravenous injection at a dose of 6 g m-2. No responses were
seen in the study, but only three patients received more than
one course at 6 gm2 or more. Because of its potency in
inhibiting the target enzyme and its potential use in combina-
tion (Elford et al., 1991), it was deemed worthwhile to test
further the potential anti-cancer activity of didox in phase II
trials. We report here on its evaluation in advanced breast
cancer.
Patients and methods
Eligible patients had locally recurrent or metastatic his-
tologically confirmed carcinoma of the breast. They had
measurable and/or evaluable lesions which were progressing
at the time of entry into the study. Patients in whom one or
more of the following were the only manifestations of disease
were excluded: lymphoedema, hilar enlargement, pleural
effusion, ascites, metastases in the central nervous system,
bone marrow suppression, osteoblastic skeletal lesions.
Patients were aged 70 years or less with a performance status
of <2 (WHO). Baseline blood count had a haemoglobin of
> lOg dl-', total white blood cell count > 3 x I09 1'- and a
platelet count of > 100 x 109 1'-l. Serum biochemistry showed
a bilirubin of <20 mmol 1`, liver transaminases < 1.5 x the
upper limit of normal for the laboratory and a creatinine of
<150 mmol 1'.
Patients had received at least one, but not more than two,
prior standard chemotherapy regimens for advanced disease.
They had received no chemotherapy during the previous 3
weeks (6 weeks in the case of mitomycin C). Prior endocrine
treatment with either oestrogens, androgens or progestogens
had been stopped for at least 4 weeks before starting didox.
Patients were excluded if all measurable and/or evaluable
disease had previously been irradiated. If there had been
prior extensive radiotherapy to the skeleton, 4 weeks had to
have elapsed before entry to the study with resolution of any
myelosuppression.
Patients had not had any previous or current malignancies
at other sites except for adequately treated in situ carcinoma
of the cervix uteri, or basal or squamous cell carcinoma of
the skin. Patients who were poor medical risks because of
non-malignant systemic disease or active infection were not
eligible for the trial.
The trial protocol was approved by local committees on
ethical practice and patients gave Written informed consent to
participate in the trial.
Didox was supplied in solution (1 G in 50 ml) through the
CRC Phase I/II Committee from Dr R. Vezin (University of
Strathclyde). It was administered in a dose of 6 gm-2 by
intravenous infusion in 3L normal saline over 36 h. Patients
were observed for a minimum 24h after the infusion to
ensure an adequate urinary output and to observe for any
signs of hypotension. Metoclopramide was given as pro-
phylactic anti-emetic cover. Treatment was repeated every 3
weeks. It was intended to give at least two courses of
treatments for evaluation of response, but patients were still
considered evaluable as treatment failures if disease was pro-
gressive after the first course. Concomitant radiotherapy was
permitted for the control of pain, and, provided that all
evaluable lesions were not included in the irradiated field, the
patient remained assessable for response to didox.
Before starting didox, patients had a full history and
physical examination, full blood count, biochemical screen,
chest radiograph and bone scan. Radiographs were taken of
abnormal areas on the bone scan. Lesions were selected for
assessment purposes and re-assessed periodically throughout
treatment. Assessment of response was based on UICC
criteria (Hayward et al., 1977). The duration of response was
to be timed from the date of commencement of treatment
until the date of documented progressive disease. Survival
was from the start of treatment.
It was planned initially to enter 14 patients into the trial
and terminate entry if no responses were seen. This was to
ensure that if the drug was active in >,20% of patients, the
chance of erroneously rejecting the drug after the first 14
patients was <0.05.
Results
Of 16 patients registered for the trial, two were excluded as
ineligible; one had three prior chemotherapy regimens, the
other had active infection under treatment and died 6 days
after starting didox.
The 14 eligible patients had a median age of 58 years
(range 40-69). Performance status was 0 in one, 1 in 11 and
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2 in two. Ten patients had operable disease at presentation
with a median post-operative disease-free interval of 32
months (range 10-138). Twelve had a median of 2 prior
endocrine treatments (range 1-5). Previous chemotherapy
regimens included anthracyclines (12 patients), the combina-
tion of cyclophosphamide, methotrexate and 5-fluorouracil
(5), mitomycin C with vinblastine (1), chlorambucil (1) and
mitoxantrone (1). Metastatic patterns included involvement
at the following sites: skin and chest wall (12 patients),
lymphatic (9), breast (4), bone (6), lungs/pleura (6), liver (2).
The median time from the diagnosis of breast cancer to
starting didox was 62 months (range 18-198).
Thirty-two courses of didox were administered with a
median of two for each patient (range 1-4). No patient
responded to didox, all having progressive disease within 2
months of starting treatment. Twelve patients have died;
median survival was 3.5 months (range 1.5-12).
Toxicity was mild. There was no significant myelotoxicity.
In 32 courses of treatment, nausea/vomiting was recorded on
ten occasions of severity WHO grade 1 (5), grade 2 (2) and
grade 3 (3). Two patients developed grade 3 alopecia. There
was no other significant toxicity.
Discussion
Ribonucleotide reductase inhibitors, notably hydroxyurea
have not had wide application in the treatment of cancer.
The potency of didox as an enzyme inhibitor and its activity
in experimental systems has led to its clinical testing. In this
study, we have demonstrated no activity for a particular
schedule against advanced breast cancer in patients who have
had prior chemotherapy. For this cancer, several useful
systemic treatments exist, both hormonal and cytotoxic, for
the palliation of metastatic disease. The availability of stan-
dard treatments make this cancer a difficult test bed for new
agents such as didox because they are usually given, as in this
trial, to patients who have already been exposed to several
different treatments. They are at a late stage in the clinical
course of the disease and resistance to further treatments is
likely.
The schedule of treatment used in this study was deter-
mined from a phase I study (Veale et al., 1988). Possibly
other schedules of didox could have greater efficacy; the
relative lack oftoxicity noted in this study might suggest that
higher dose intensity is needed. Nevertheless, despite these
mitigating comments, the disappointing results in the study
do not encourage further testing of didox as a single agent in
metastatic breast cancer.
The preclinical data indicating potentiation of other
agents, perhaps by inhibiting rates of DNA repair, leave the
possibility open for further studies using didox with certain
other drugs. As with other antimetabolites, such as cytosine-
arabinoside, a daily schedule over several days might be more
efficacious. Any future studies with didox will need to explore
different schedules.
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